Khosla S |
Magic bullets to kill nasty osteoclasts. |
2005 |
Endocrinology |
pmid:16009971
|
Feng X |
RANKing intracellular signaling in osteoclasts. |
2005 |
IUBMB Life |
pmid:16012047
|
Stenman UH et al. |
Prognostic value of serum markers for prostate cancer. |
2005 |
Scand J Urol Nephrol Suppl |
pmid:16019759
|
Li J et al. |
[Effect of raloxifene and estradiol on the biological function and osteoprotegerin expression of osteoblasts in vitro]. |
2005 |
Di Yi Jun Yi Da Xue Xue Bao |
pmid:16027068
|
Pipes GD et al. |
Optimization and applications of CDAP labeling for the assignment of cysteines. |
2005 |
Pharm. Res. |
pmid:16028006
|
Yang S et al. |
Muramyl dipeptide enhances osteoclast formation induced by lipopolysaccharide, IL-1 alpha, and TNF-alpha through nucleotide-binding oligomerization domain 2-mediated signaling in osteoblasts. |
2005 |
J. Immunol. |
pmid:16034140
|
Deschner J et al. |
Regulation of RANKL by biomechanical loading in fibrochondrocytes of meniscus. |
2006 |
J Biomech |
pmid:16038916
|
Guang-da X et al. |
Changes in plasma concentrations of osteoprotegerin before and after levothyroxine replacement therapy in hypothyroid patients. |
2005 |
J. Clin. Endocrinol. Metab. |
pmid:16046585
|
Kazama JJ et al. |
Maxacalcitol therapy decreases circulating osteoprotegerin levels in dialysis patients with secondary hyperparathyroidism. |
2005 |
Clin. Nephrol. |
pmid:16047647
|
Zahanich I et al. |
Molecular and functional expression of voltage-operated calcium channels during osteogenic differentiation of human mesenchymal stem cells. |
2005 |
J. Bone Miner. Res. |
pmid:16059635
|
Cao JJ et al. |
Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse. |
2005 |
J. Bone Miner. Res. |
pmid:16059637
|
Terpos E et al. |
The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. |
2005 |
Leukemia |
pmid:16079895
|
Huang P et al. |
[In vitro study of combination rhOPG-Fc and alendronate on inhibition osteoclast]. |
2005 |
Zhonghua Wai Ke Za Zhi |
pmid:16083587
|
Kwon OH et al. |
The hematopoietic transcription factor PU.1 regulates RANK gene expression in myeloid progenitors. |
2005 |
Biochem. Biophys. Res. Commun. |
pmid:16083856
|
Hayton MJ et al. |
Involvement of adenosine 5'-triphosphate in ultrasound-induced fracture repair. |
2005 |
Ultrasound Med Biol |
pmid:16085103
|
von Knoch F et al. |
Suppression of polyethylene particle-induced osteolysis by exogenous osteoprotegerin. |
2005 |
J Biomed Mater Res A |
pmid:16088891
|
Ashcroft AJ and Carding SR |
RANK ligand and osteoprotegerin: emerging roles in mucosal inflammation. |
2005 |
Gut |
pmid:16099805
|
Zojer N et al. |
Bisphosphonate treatment does not affect serum levels of osteoprotegerin and RANKL in hypercalcemic cancer patients. |
2005 Sep-Oct |
Anticancer Res. |
pmid:16101188
|
Lems WF and Bijlsma JW |
[Clinical implications of new insights into the regulation of bone resorption]. |
2005 |
Ned Tijdschr Geneeskd |
pmid:16104110
|
Daroszewska A and Ralston SH |
Genetics of Paget's disease of bone. |
2005 |
Clin. Sci. |
pmid:16104845
|
Rogers A and Eastell R |
Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. |
2005 |
J. Clin. Endocrinol. Metab. |
pmid:16105967
|
Wise GE et al. |
CSF-1 regulation of osteoclastogenesis for tooth eruption. |
2005 |
J. Dent. Res. |
pmid:16109994
|
Yang KC et al. |
[Effect of nylestriol and levonorgestrel on the expression of Opg/OPGL in human osteosarcoma MG-63 cell lines]. |
2004 |
Zhong Nan Da Xue Xue Bao Yi Xue Ban |
pmid:16114553
|
Ziegler S et al. |
Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. |
2005 |
Atherosclerosis |
pmid:16115489
|
Gonnelli S et al. |
Osteoprotegerin (OPG) and receptor activator of NF-kB ligand (RANK-L) serum levels in patients on chronic hemodialysis. |
2005 |
J. Endocrinol. Invest. |
pmid:16117195
|
Zhou Z et al. |
Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma. |
2005 |
Cancer |
pmid:16121404
|
Avignon A et al. |
Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. |
2005 |
Diabetes Care |
pmid:16123486
|
Kusumi A et al. |
Regulation of synthesis of osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand in normal human osteoblasts via the p38 mitogen-activated protein kinase pathway by the application of cyclic tensile strain. |
2005 |
J. Bone Miner. Metab. |
pmid:16133687
|
Deftos LJ |
Treatment of Paget's disease--taming the wild osteoclast. |
2005 |
N. Engl. J. Med. |
pmid:16135831
|
Cundy T et al. |
Recombinant osteoprotegerin for juvenile Paget's disease. |
2005 |
N. Engl. J. Med. |
pmid:16135836
|
Su X et al. |
[Effects of parathyroid hormone on osteoprotegerin expression and osteoprotegerin ligand and their related cytokines in human osteoblasts]. |
2004 |
Zhong Nan Da Xue Xue Bao Yi Xue Ban |
pmid:16137047
|
Heinrich J et al. |
CSF-1, RANKL and OPG regulate osteoclastogenesis during murine tooth eruption. |
2005 |
Arch. Oral Biol. |
pmid:16137499
|
Moschen AR et al. |
The RANKL/OPG system and bone mineral density in patients with chronic liver disease. |
2005 |
J. Hepatol. |
pmid:16143421
|
Yang YQ et al. |
Human periodontal ligament cells express osteoblastic phenotypes under intermittent force loading in vitro. |
2006 |
Front. Biosci. |
pmid:16146769
|
Takahashi N et al. |
[Osteoprotegerin (OPG)]. |
2005 |
Nippon Rinsho |
pmid:16149650
|
Choi JY et al. |
Genetic polymorphisms of OPG, RANK, and ESR1 and bone mineral density in Korean postmenopausal women. |
2005 |
Calcif. Tissue Int. |
pmid:16151677
|
Viereck V et al. |
Atorvastatin stimulates the production of osteoprotegerin by human osteoblasts. |
2005 |
J. Cell. Biochem. |
pmid:16152630
|
Crisafulli A et al. |
Osteoprotegerin and bone mineral density in hemodiafiltration patients. |
2005 |
Ren Fail |
pmid:16152990
|
Lau YS et al. |
Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue. |
2005 |
Hum. Pathol. |
pmid:16153456
|
Zhou YQ et al. |
[OPG and OPGL expression in condyle cartilage of temporomandibular joint following anterior disc displacement]. |
2005 |
Shanghai Kou Qiang Yi Xue |
pmid:16155701
|
Holen I et al. |
Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo--a role in tumour cell survival? |
2005 |
Breast Cancer Res. Treat. |
pmid:16155791
|
Hong JS et al. |
Maternal plasma osteoprotegerin concentration in normal pregnancy. |
2005 |
Am. J. Obstet. Gynecol. |
pmid:16157103
|
Raustyte G et al. |
Calcium deposition and expression of bone modelling markers in the tympanic membrane following acute otitis media. |
2006 |
Int. J. Pediatr. Otorhinolaryngol. |
pmid:16159670
|
Stolina M et al. |
RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. |
2005 |
J. Bone Miner. Res. |
pmid:16160733
|
Yasuda H |
[OPG, anti-rANKL antibody]. |
2005 |
Nippon Rinsho |
pmid:16164225
|
Ueland T and Bollerslev J |
Bone metabolism and growth hormone deficiency. Experimental and clinical aspects. |
2005 |
Front Horm Res |
pmid:16166760
|
Ulrich-Vinther M et al. |
Gene therapy with human osteoprotegerin decreases callus remodeling with limited effects on biomechanical properties. |
2005 |
Bone |
pmid:16169783
|
Hjertner Ø et al. |
Identification of new targets for therapy of osteolytic bone disease in multiple myeloma. |
2005 |
Curr Drug Targets |
pmid:16178802
|
Nardelli B et al. |
Osteostat/tumor necrosis factor superfamily 18 inhibits osteoclastogenesis and is selectively expressed by vascular endothelial cells. |
2006 |
Endocrinology |
pmid:16179414
|
Kostenuik PJ |
Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. |
2005 |
Curr Opin Pharmacol |
pmid:16188502
|
Sakakura Y et al. |
Immunolocalization of receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin (OPG) in Meckel's cartilage compared with developing endochondral bones in mice. |
2005 |
J. Anat. |
pmid:16191162
|
Meng XM et al. |
[Expression of receptor activator of NF-kappa B ligand and osteoprotegerin protein in the giant cell lesions of jaw]. |
2005 |
Zhonghua Kou Qiang Yi Xue Za Zhi |
pmid:16191370
|
Tabuchi M et al. |
Enhancement of crude bone morphogenetic protein-induced new bone formation and normalization of endochondral ossification by bisphosphonate treatment in osteoprotegerin-deficient mice. |
2005 |
Calcif. Tissue Int. |
pmid:16193235
|
Otsuka T et al. |
Enamel matrix derivative promotes osteoclast cell formation by RANKL production in mouse marrow cultures. |
2005 |
J Dent |
pmid:16199283
|
Neumann E et al. |
The RANK/RANKL/osteoprotegerin system in rheumatoid arthritis: new insights from animal models. |
2005 |
Arthritis Rheum. |
pmid:16200575
|
Liu D et al. |
Chronology and regulation of gene expression of RANKL in the rat dental follicle. |
2005 |
Eur. J. Oral Sci. |
pmid:16202028
|
Xie F et al. |
Increase in bone mass and bone strength by Sambucus williamsii HANCE in ovariectomized rats. |
2005 |
Biol. Pharm. Bull. |
pmid:16204939
|
Juarranz Y et al. |
Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis. |
2005 |
Arthritis Res. Ther. |
pmid:16207319
|
Görtz B et al. |
Tumour necrosis factor activates the mitogen-activated protein kinases p38alpha and ERK in the synovial membrane in vivo. |
2005 |
Arthritis Res. Ther. |
pmid:16207331
|
Pantsulaia I et al. |
Contribution of the familial and genetic factors on monocyte chemoattractant protein-1 variation in healthy human pedigrees. |
2005 |
Cytokine |
pmid:16213155
|
Low E et al. |
Expression of mRNA for osteoprotegerin and receptor activator of nuclear factor kappa beta ligand (RANKL) during root resorption induced by the application of heavy orthodontic forces on rat molars. |
2005 |
Am J Orthod Dentofacial Orthop |
pmid:16214633
|
Schneeweis LA et al. |
Functional dissection of osteoprotegerin and its interaction with receptor activator of NF-kappaB ligand. |
2005 |
J. Biol. Chem. |
pmid:16215261
|
Bezerra MC et al. |
Low bone density and low serum levels of soluble RANK ligand are associated with severe arterial calcification in patients with Takayasu arteritis. |
2005 |
Rheumatology (Oxford) |
pmid:16219645
|
Minenna G et al. |
[RANKL/RANK, OPG and OPT in a group of patients affected by chronic arthritis. Preliminary report]. |
2005 |
Recenti Prog Med |
pmid:16229324
|
Zwerina J et al. |
Heme oxygenase 1 (HO-1) regulates osteoclastogenesis and bone resorption. |
2005 |
FASEB J. |
pmid:16234431
|
Viereck V et al. |
Isopropanolic extract of black cohosh stimulates osteoprotegerin production by human osteoblasts. |
2005 |
J. Bone Miner. Res. |
pmid:16234977
|
Gajewska J et al. |
[The impairement of bone formation and resorption in 25-year-old man with neglected celiac disease]. |
2005 |
Wiad. Lek. |
pmid:16238129
|
Ruocco MG and Karin M |
IKK{beta} as a target for treatment of inflammation induced bone loss. |
2005 |
Ann. Rheum. Dis. |
pmid:16239395
|
Anandarajah AP and Schwarz EM |
Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications. |
2006 |
J. Cell. Biochem. |
pmid:16240334
|
Palma MA and Body JJ |
Usefulness of bone formation markers in breast cancer. |
2005 Jul-Sep |
Int. J. Biol. Markers |
pmid:16240842
|
Hsu YH et al. |
Variation in genes involved in the RANKL/RANK/OPG bone remodeling pathway are associated with bone mineral density at different skeletal sites in men. |
2006 |
Hum. Genet. |
pmid:16249885
|
Palmqvist P et al. |
Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway. |
2006 |
J. Biol. Chem. |
pmid:16251181
|
Xiao HL et al. |
[Expression and activity determination of TNFR domain of osteoprotegerin in E.coli and corresponding antibody preparation]. |
2005 |
Yi Chuan |
pmid:16257908
|
Liu W et al. |
Receptor activator of NF-kappaB (RANK) cytoplasmic motif, 369PFQEP373, plays a predominant role in osteoclast survival in part by activating Akt/PKB and its downstream effector AFX/FOXO4. |
2005 |
J. Biol. Chem. |
pmid:16260781
|
Yeung RS |
Bones, blood vessels, and the immune system: what's the link? |
2005 |
J. Rheumatol. |
pmid:16265680
|
Simonini G et al. |
Osteoprotegerin serum levels in Kawasaki disease: an additional potential marker in predicting children with coronary artery involvement. |
2005 |
J. Rheumatol. |
pmid:16265708
|
Tanaka H et al. |
Nicotine and lipopolysaccharide stimulate the formation of osteoclast-like cells by increasing macrophage colony-stimulating factor and prostaglandin E2 production by osteoblasts. |
2006 |
Life Sci. |
pmid:16266722
|
Kim SM et al. |
Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity. |
2005 |
Clin. Endocrinol. (Oxf) |
pmid:16268814
|
Secchiero P et al. |
Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells. |
2006 |
J. Cell. Physiol. |
pmid:16270354
|
Tarquini R et al. |
Circasemidian rather than circadian variation of circulating osteoprotegerin in clinical health. |
2005 |
Biomed. Pharmacother. |
pmid:16275499
|
Cozzani M et al. |
Transcription Factor Decoy (TFD) as a novel approach for the control of osteoclastic resorption. |
2005 |
Prog Orthod |
pmid:16276433
|
Gaudio A et al. |
Hepatic osteodystrophy: does the osteoprotegerin/receptor activator of nuclear factor-kB ligand system play a role? |
2005 |
J. Endocrinol. Invest. |
pmid:16277162
|
Taubman MA et al. |
Immune response: the key to bone resorption in periodontal disease. |
2005 |
J. Periodontol. |
pmid:16277573
|
Bartold PM et al. |
Periodontitis and rheumatoid arthritis: a review. |
2005 |
J. Periodontol. |
pmid:16277578
|
Kaji H et al. |
Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures. |
2005 |
Horm. Metab. Res. |
pmid:16278780
|
Morena M et al. |
Plasma osteoprotegerin is associated with mortality in hemodialysis patients. |
2006 |
J. Am. Soc. Nephrol. |
pmid:16280472
|
Kishimoto K et al. |
Expression profile of genes related to osteoclastogenesis in mouse growth plate and articular cartilage. |
2006 |
Histochem. Cell Biol. |
pmid:16283360
|
Wise GE et al. |
Injections of osteoprotegerin and PMA delay tooth eruption. |
2006 |
Clin Anat |
pmid:16283633
|
Cross SS et al. |
Osteoprotegerin (OPG)--a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? |
2006 |
Int. J. Cancer |
pmid:16287088
|
Schoppet M et al. |
TNF-related apoptosis-inducing ligand and its decoy receptor osteoprotegerin in nonischemic dilated cardiomyopathy. |
2005 |
Biochem. Biophys. Res. Commun. |
pmid:16288714
|
Michael H et al. |
Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. |
2005 |
J. Bone Miner. Res. |
pmid:16294275
|
Nicholls BM et al. |
Limited rescue of osteoclast-poor osteopetrosis after successful engraftment by cord blood from an unrelated donor. |
2005 |
J. Bone Miner. Res. |
pmid:16294279
|
Andelković Z et al. |
[Osteoprotegerin--a neutralizing receptor, protector of bones and a potential antiresorptive agent]. |
2005 Jul-Aug |
Med. Pregl. |
pmid:16296579
|
Hormdee D et al. |
Protein kinase-A-dependent osteoprotegerin production on interleukin-1 stimulation in human gingival fibroblasts is distinct from periodontal ligament fibroblasts. |
2005 |
Clin. Exp. Immunol. |
pmid:16297161
|
Humphrey EL et al. |
Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells. |
2006 |
Bone |
pmid:16298558
|
Geusens P and Reid D |
Newer drug treatments: their effects on fracture prevention. |
2005 |
Best Pract Res Clin Rheumatol |
pmid:16301192
|
Hamdy NA |
Osteoprotegerin as a potential therapy for osteoporosis. |
2005 |
Curr Osteoporos Rep |
pmid:16303111
|
Wiercinska-Drapalo A et al. |
Transforming growth factor beta1 and prostaglandin E2 concentrations are associated with bone formation markers in ulcerative colitis patients. |
2005 |
Prostaglandins Other Lipid Mediat. |
pmid:16303613
|
Yang M et al. |
Chemokine and chemokine receptor expression during colony stimulating factor-1-induced osteoclast differentiation in the toothless osteopetrotic rat: a key role for CCL9 (MIP-1gamma) in osteoclastogenesis in vivo and in vitro. |
2006 |
Blood |
pmid:16304045
|
Pettersen I et al. |
Osteoprotegerin is expressed in colon carcinoma cells. |
2005 Nov-Dec |
Anticancer Res. |
pmid:16309167
|